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Abstract: Among the gynaecological malignancies, ovarian cancer is one of the neoplastic forms with the poorest prog-
nosis and with the bad overall and disease-free survival rates than other gynaecological cancers; several studies, analyzing 
clinical data and pathological features on ovarian cancers, have focused on the identification of both diagnostic and prog-
nostic markers for applications in clinical practice. High-throughput technologies have accelerated the process of bio-
marker discovery, but their validity should be still demonstrated by extensive researches on sensibility and sensitivity of 
ovarian cancer novel biomarkers, determining whether gene profiling and proteomics could help differentiate between pa-
tients with metastatic ovarian cancer and primary ovarian carcinomas, and their potential impact on management. 
Therefore, considerable interest lies in identifying molecular prognostic biomarkers and protein indicators to guide treat-
ment decisions and clinical follow up; the current state of knowledge about the potential clinical value of gene expression 
profiling in ovarian cancer is discussed, focusing on three main areas: distinguishing normal ovarian tissue from ovarian 
tumors, identifying different subtypes of ovarian cancer and identifying cancer likely to be responsive to therapy. 
In this elaborate we discuss the use of novel molecules, discovered by proteomics and genomics approaches, as potential 
protein biomarkers in the management of ovarian cancer, to improve the anticancer therapy for malignant ovarian tumors 
and to monitor the clinical follow up. 
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INTRODUCTION 
  Despite enormous progress in cancer research, this dis-
ease represents one of the principal causes of death world-
wide. For many types of cancer, the stage at the moment of 
diagnosis is relevant for the successive treatment; therefore, 
there is a need for the identification of molecules which can 
act as indicators of an early malignant process, when disease 
burden is localized. However, the possibility to use many of 
these molecules in the clinical practice remains, unfortu-
nately, still elusive. 
  Evaluation and validation of biomarkers need rigorous 
procedures to ensure clinical validity.  
  The process follows different steps to assist researchers 
in developing biomarker, these phases include: preclinical 
exploratory studies, clinical assay and validation, retrospec-
tive longitudinal, prospective screening and cancer control 
[1].  
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  In addition, genomic and proteomics technologies have 
increased the number of potential biomarker entering clinical 
development, hence the validation of these candidate bio-
markers require an integrated effort among government, aca-
demic and pharmaceutical groups to coordinate the activity 
of many laboratories [2]. 
  In the case of ovarian cancer, it is often reported the evi-
dence that different histological subtypes of ovarian cancer 
can be distinguished by some microarray profilings, and that 
these subtypes might be partly reflected by a different aetiol-
ogy through the deregulation and activation of different 
pathways.  
  This neoplasm heterogeneity could also account for dif-
ferent ovarian tumor behaviours and it could be revealed by 
specific biomarkers; for this evidence, it is reported by 
authors that gene expression profiling could be a useful 
prognostic tool, predicting chemosensitivity to the standard 
treatment combination of paclitaxel and platinum chemo-
therapy for advanced ovarian cancer, but more knowledge 
about chemosensitivity could eventually lead to a more tai-
lored cancer therapy [1-3]. 
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  The purpose of this review is to summarize current data 
regarding the use of novel protein biomarkers, based on ge-
nomics and proteomics, in the diagnosis, prognosis and re-
sponse to therapy in ovarian cancer. Our attention will be 
focus not only on serum markers but also on intracellular 
proteins. Indeed, the expression of these proteins can reflect 
cellular and molecular mechanisms that control onset and 
neoplastic progression. Proteins included in this group be-
long to different cellular pathways including cellular me-
tabolism and signal transduction. Of particular interest, it is 
the role of signalling molecules that regulate interaction 
pathways between tumour cells and the microenvironment. 
OVARIAN CANCER: MARKERS ACTUALLY USED 
IN CLINIC PRACTICE 
  Worldwide ovarian cancer accounts for approximately 
32% of gynaecological malignancies and represents 55% of 
female mortality associated with cancer. Widely asympto-
matic at the moment of the diagnosis, more than 70% of the 
patients with ovarian cancer are already in an advanced dis-
ease state [3]. 
  The serum CA125 in combination with transvaginal or 
transabdominal ultrasonography (US) have been helpful for 
clinicians in the diagnosis and monitoring of a suspicious 
ovarian formation, leading to their acceptance for clinical 
screening [4], since US is a non-invasive acceptable proce-
dure with a large diffusion in world women screening pro-
grams and without complications. 
  The CA125, identified in 1981, is the only serum mole-
cules significantly associated with ovarian cancer. Normally, 
serum levels are less than 35 U/ml and are increased in about 
90% of patients with advanced ovarian cancer (stage III-IV) 
but only in 50% of women with early stage disease. This 
protein belongs to the protein family of mucins, a high mo-
lecular weight protein that normally coats the epithelium [5, 
6]. In virtue of their localization, mucine proteins have ex-
tremely important functions in cellular physiology, like, for 
example, cellular adhesion. Alterations in their oligosaccha-
ride structure have been noticed in different cancer forms 
[7]. 
  CA 125 is a useful marker for the assessment of response 
to chemotherapy, predicting relapses and for discrimination 
between benign and malignant masses [8, 9].  
  The development of an algorithm that calculates risk of 
ovarian cancer, based on serial CA125 values, has shown 
that 20% of ovarian cancers have little or no expression of 
CA125 and has pointed out the importance of additional se-
rum markers identification, as well as of new molecules ca-
pable of completing or replacing CA125 altogether, to facili-
tate earlier detection of ovarian cancer [10]. 
  US in combination with CA125 has also been suggested 
as a potential means for early detection of ovarian cancer 
[11]; others studies confirmed the efficacy of this combina-
tion for the screening of general populations and high risk 
people [12].  
  For this reason, evaluation of a cystic formation with US 
characteristic of benignity, should lead to a normal echo-
graphic follow-up [11-13].  
  However, additional studies performed with echographic 
screening have not demonstrated adequate sensitivity and 
sensibility for an early diagnosis of ovarian cancer [14]. 
  Hereby, in ovarian cancer types detecting, good results 
were obtained by the combination of CA125 with others 
serum markers; serum total inhibin levels are sensitive and 
specific markers of epithelial ovarian cancer in postmeno-
pausal women; the production of inhibin by the ovaries al-
most stops after the menopause, but it continues from ovar-
ian tumors [15]. 
  After menopause, circular inhibin levels are undetectable; 
on the other hand, they are elevated in women with ovarian 
cancer [15]. 
  Inhibin is a glycoprotein that exists as a dimeric form of 
two subunits ( and A or B), to form inhibin A and inhibin 
B (A) and B (B); moreover, inhibin seems to be com-
plementary to CA125 and both markers have a total 95% of 
sensitivity with 95% of specificity.  
  Studies are directed toward establishing whether there are 
cancer specific inhibin forms, which may be suitable during 
the reproductive years, when these proteins show substantial 
fluctuations that would seriously compromise a preoperative 
assessment of any ovarian cancer [16]. 
NEW PROTEIN MARKERS IN OVARIAN CANCER 
  Mesothelin is a cell surface protein present on normal 
mesothelial cells lining the body cavities and it is highly ex-
pressed in several cancers, including ovarian cancers. 
  Using mice lacking the Mesothelin gene, researchers 
have developed a monoclonal antibody directed against the 
protein and an ELISA assay for detecting serum mesothelin 
levels.  
  Elevated proteins levels have been detected in patients 
with mesothelioma and ovarian cancer [17]. Moreover, pro-
tein levels increase from the earlier form to more advanced 
cancer forms [18].  
  Serum mesothelin may be a useful test to monitor treat-
ment response in mesothelin-expressing cancers, because 
after surgery there is a rapid decrease in mesothelin levels in 
patients with peritoneal mesothelioma. Future studies corre-
lating serum mesothelin with detailed clinical information, 
such as tumour stage, tumour bulk, and response to treat-
ment, will also have to be done to determine if serum meso-
thelin has prognostic significance and also if it can be used 
as a biomarker to assess response to other therapies besides 
surgery [17]. 
  Important results have been obtained even in prognosis 
and in monitoring response to therapy. Signal Transducer 
and Activator of Transcription 3 (STAT3) is a latent tran-
scription factor in several neoplastic diseases; it normally 
resides in the cytoplasm and can be activated thought phos-
phorilation by several cytokines, hormones and growth fac-
tor that play their roles using STAT3 activated pathway, 
regulating different biological responses, like cell develop-
ment, differentiation, proliferation, motility, and survival 
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  Expression of phosphorilated STAT3 form is increased in 
primary ovarian cancer and its nuclear localization is associ-
ated with a poor prognosis; further studies are needed to elu-
cidate the mechanism of activation of Stat3, its effects on 
downstream targets, and its role in the neoplastic transforma-
tion of epithelial ovarian cells [20]. 
 LPAAT- (of which we know six human isoforms) is an 
enzyme that catalyzes the acetylation of lysophosphatidic 
acid (LPA), generating phosphatidic acid (PA), acting as a 
second messenger in tumour cell regulation of both prolifera-
tive and survival pathways [21].  
  An increase of enzyme expression has been correlated to 
a poor prognosis and is associated with a minor survival 
[22]; in SK-OV-3 and IGROV1 cell lines, small interfering 
RNA (siRNA) was used to silence the expression of 
LPAAT- reducing ovarian cancer cell lines viability [23]. 
 LPAAT- is an intriguing prognostic tool for the identifi-
cation of high-risk epithelial ovarian cancer (EOC) and it 
should be a molecular target toward which to direct therapy, 
because of the adverse clinical outcome associated with 
LPAAT- expression, even for early-stage ovarian tumours 
[24]. 
  Among prognostic factors in ovarian cancers there are 
many members of Human Kallikrein Family (hK), of serine 
proteases.  
  This family gene is organized in a big cluster, located in 
19q13.4 chromosome; different himmunohistochemistry 
studies have shown that hK8 could be considered a marker 
of positive prognosis in patients with ovarian cancer [25, 
26].  
  In addition to hK8, extensive correlative clinical data 
have linked the over expression of 11 other kallikreins to 
ovarian cancer patient prognosis [27].  
  Although most reports link high kallikrein expression 
with poor patient prognosis (e.g., kallikreins 4, 5, 6, 7, 10, 
and 15), several studies also recognize some kallikreins as 
favourable prognostic indicators (e.g., kallikreins 9, 11, 13, 
and 14) [28].  
  These clinical findings seem to be contradictory but have 
been explained by authors considering that hKs and prote-
ases in general, have a dual role during tumour progression. 
  Pyruvate kinase (PK) is a key enzyme in glycolysis; the 
isoenzyme M2-PK is shifted to a dimeric form in a variety of 
tumours. Since the dimeric form is over-expressed in tumour 
cells, it is called pyruvate kinase tumour M2 (Tu M2-PK) 
[29].  
  Tu M2-PK is present in body fluids also, most likely re-
leased from tumour cells by tumour necrosis and cell turn-
over. It has been previously shown for various tumours that 
Tu M2-PK determination in the circulation provides excel-
lent discrimination between benign and malignant disease or 
may provide additional information regarding sensitivity to 
chemotherapy [30-32]. 
  In a recent study of Ahmed et al., it has been supposed a 
possible link between TuM2-PK plasmatic levels and ovar-
ian cancer malignancy showing that its concentration was 
significantly raised in ovarian cancer patients, particularly 
those with higher stage disease [33].  
  In another study, the same researchers have tried to de-
termine the cut-off values for TuM2-PK sensitivity and 
specificity for differentiating between benign and malignant 
ovarian disease.  
  The average M2-PK concentration in cancer patients was 
52 U/ml versus 27 U/ml in patients with benign conditions (p 
< 0.001). At a cut-off value of 22 U/ml the sensitivity of M2-
PK for detecting cancer was 70% with a specificity of 65%.  
  However the M2-PK role in clinical practice needs fur-
ther evaluation [34]. 
 c-MET  (Mesenchymal epithelial transition factor) is a 
proto-oncogene that encodes for a tyrosine kinase membrane 
receptor [35].  
  The c-Met protein is expressed mostly in in mammalian 
tissues and plays an important role in different cellular proc-
esses; its ligand is the HGF (Hepatocyte Growth Factor), 
known also as Scatter Factor (SF) and c-MET over-
expression or inactivation is implicated in different tumoral 
disease [35]. 
 Recently,  Sawada  et al. have analyzed c-MET role in 
ovarian cancer biology and its possible implication as a 
therapeutic target; so, it has been established the c-MET 
over-expression, especially in patients in higher stage disease 
[36].  
  That c-MET level could represent a potential prognostic 
marker for patient with higher stage EOC has already been 
shown by the studies of Ayhan et al. [37]. Sawada et al. pro-
vided evidence that the silencing of c-MET messenger in 
SKOV-3ip1 cells caused inhibition of cellular adhesion to 
different extra cellular matrix components and human pri-
mary mesothelial cells; in parallel a significative reduction of 
-integrin and -integrin, urokinase and matrix metalloprote-
inase (MMP)-2/MMP-9 activity has been observed.  
  In summary, this study shows that c-Met is highly ex-
pressed in a subset of ovarian cancer patients and that its 
inhibition can reduce adhesion, invasion, metastasis, and 
ultimately tumour burden. It is tempting to speculate that, 
after the optimal surgical debulking of a patient with ovarian 
cancer, consolidation therapy with a drug that targets metas-
tasis will delay the repopulation of the peritoneal cavity by 
ovarian cancer cells [36]. 
  Moreover, in 2003 Maggiora et al. have established a 
link between c-MET and RON, another member of Tyrosin-
kinase receptor gene family, whose mutation is related to 
tumorigenesis.  
  It has been demonstrated that, in vitro, RON and MET 
receptors cross-talk, synergize in intracellular signalling, and 
cooperate in inducing morphogenic responses; the same are 
significantly co-expressed in 42% (P < 0.001), hypothesizing 
that their action might promote ovarian cancer progression 
[38]. 
  Even if many possible biomarkers are directly produced 
by tumoural cells, recent evidences draw our attention to 
tumour microenvironment, not only as an important factor in  
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carcinogenesis, but also as a source of new markers. In fact, 
tumoural environment is constituted by a different cellular 
type system, like macrophages, fibroblasts, endothelial cells, 
lymphocytes, that actively attend to the tumoural progression 
process, through production of different molecules, measur-
able in biological fluids [39]. 
  Matrix metalloproteinase (MMP) are a group of calcium-
zinc dependent photolytic enzymes, capable of reducing 
many extra cellular matrix component; they can be produced 
by tumoural and stromal cells [40].  
  In stromal cells, high levels of MMP-2, MMP-9 e MT1-
MPP, (a subgroup of no soluble enzymes, connected to cel-
lular membrane) are linked to a poor prognosis in patients 
with EOC.  
  Although the role of MMPs as therapeutic targets re-
mains to be further elucidated, it is possible that broad MMP 
inhibitors (for example, Col-3) targeting both epithelial and 
stromal MMPs may be useful in controlling ovarian cancer 
vascularization and metastasis [41]. 
  EphA2 is a tyrosine-kinase receptor of 130KDa, belong-
ing to Eph family; EphA2 is over-expressed in many can-
cers, including ovarian cancer, in which its expression is 
related to more aggressive cancer behaviour [42].  
 Interestingly, the EphA2 gene is located on chromosome 
1p36.1, which is not only a genetic “hot spot” in cancer [43, 
44], but also the  second most common site of complex 
karyotypic abnormalities in ovarian cancer [45]. Dohn et al. 
[46] showed that EphA2 transcription is regulated by p53, a 
tumour suppressor protein is frequently mutated in ovarian 
cancer [47-49].  
  If further study will determine the role of p53 mutations 
in regulating EphA2 levels [47, 48], EphA2 may be a thera-
peutic target to treat ovarian carcinoma patients who have 
p53 mutations [49].  
  In addition, Hendrix et al. [50] and Hess et al. [51] have 
shown that EphA2 may play a role in vasculogenic mimicry. 
 Therefore,  targeting  EphA2  could have direct anti-
tumour and ant vascular effects.  
  EphA2 role in tumorigenesis seems to concern invasion 
and angiogenesis process; in fact, levels of this receptor in 
endothelial and tumoural cells are linked to a major density 
of micro vessels and to an high expression of MMP-9, 
MMP-2, MT1-MMP [52].  
  Therefore, EphA2 represents an important predictor of 
clinical outcome and may be a potential ant vascular thera-
peutic target. Recently Lin et al. demonstrated that targeting 
EphA2 while concomitantly using conventional cytotoxic 
chemotherapy successfully decreased tumour growth in vivo 
at least in part by inducing tumour-associated endothelial 
cell apoptosis [53], supporting EphA2 as a therapeutic 
antiangiogenic target.  
  PDEF belong to ETS transcription factor family, charac-
terized by a conservative domain of 85 aa that bind DNA. 
They are nuclear factors that participate as effectors in Ras-
MAPK pathway.  
  The mechanisms through which they seem to play a role 
in tumorigenesis or in ovarian cancer progression are still 
unknown; these factors could alter EOC physiology, possibly 
in a way similar to that studied in mammalian cancer cell 
lines, where they significantly increase mobility and inva-
sively.  
  Expression of this transcription factor has been studied, 
at mRNA and proteic level: data obtained show that 70% of 
ovarian cancer over-expressed PDEF mRNA; on the other 
hand, only in 33% of higher stage disease over-expressed 
PDEF protein [54]. 
  Different evidences suggest a link between inflammatory 
process and cancer onset [55]. 
  Many molecules produced by inflammatory tumoural or 
associated cells, like fibroblasts, play the role of mediator 
between these two processes. Cytokines are a heterogeneous 
protein family of low molecular weight proteins, produced 
by immune cells, but also by tumoural cells, that can act as 
stimulators or inhibitors of growth and tumour progression 
[56].  
  Interleukin 13 (IL-13) is another cytokine with anti-
inflammatory activity, produced by T cells, that plays an 
important role in many biological activities, including cancer 
onset. IL-13 acts linking to its membrane receptor (IL-13R), 
constituted by two strands, IL13R1 and IL13R2. An al-
terated expression of this cytokine has been observed in tu-
moural tissue, in respect to normal ovarian tissue [57].  
  High level of 2 chain has been revealed in 44 on 53 
malign ovarian cancer samples (83%) [58]. 
  Consistent with preclinical and clinical activities of IL13 
cytotoxin in phase I/II clinical trials, Kioi et al. [58] showed 
that IL-13 cytotoxin mediates antitumor activity.  
  One of the characteristics of ovarian cancer is their in-
traperitoneal (IP) spread, leading to an advanced stage of the 
disease invading other organs. Thus, the IP route of admini-
stration of therapeutic agents seems to be an appropriate 
route for disseminated ovarian cancer therapy; therefore, 
Kioi et al. investigated the efficacy of IL- 13 cytotoxin ad-
ministrated IP using either a continuous infusion pump or 
bolus administration.  
  By these routes of administration, IL-13 cytotoxin medi-
ated dramatic antitumor effects in very large established s.c. 
xenografted tumours [58] and therefore, IL-13 has been pro-
posed as promising target for ovarian cancer therapy.  
  Higher levels of serum macrophage migration inhibitory 
factor (MIF) were found in ovarian cancer patients’ blood 
(sensibility of 77,8% and specificity of 53,3%) [59].  
  Moreover, studies about co culture of macrophages with 
cancer cell lines showed that MIF expression is induced in a 
JNKII and NF-kB-dependent manner and acts inducing 
macrophages MMP release, promoting tumoural cells inva-
sively [60]. 
  MIF is an inflammatory cytokine that plays an important 
role in regulating innate and adaptive immune responses. 
The potent proinflammatory effect of MIF may mediate 
some of the stimulatory effects of inflammation on cancer 
progression; so, understanding its role on the inflammatory 
process associated with tumour development may provide 
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predisposes individuals to ovarian cancer and may open new 
venues for targeted therapy [61].  
  Attempts to provide insight into mechanisms of action of 
MIF have suggested that the protein acts by stimulating in-
flammatory signals in the ascitic microenvironment such as 
IL-6, IL-10 and TNF- [60]. 
  NGAL (neutrophil gelatinase-associated lipocalin) be-
longs to the lipocalin protein family.  
  It is a protein stored in the specific granules of human 
neutrophils and works limiting bacterial growth at sites of 
infection.  
  Lipocalins have unusual expression in tumoural tissues, 
respect to normal ones. 
  The NGAL concentration was higher in the serum of 
patients with borderline grade 1 tumours respect to grade 2 
and grade 3 ones and to benign tumour. More studies are 
needed to further evaluate the role of NGAL in the progres-
sion of ovarian carcinoma and its potential targeting in diag-
nosis and treatment [62]. 
  Tumoral cells capacity to escape to immunity surveil-
lance was proposed as one of the cancer fundamental charac-
teristic, for the first time by Dann et al. [63]. 
  One way used by cancer to escape from immunity system 
attach is the “immunosovvertion”, that is the immunity sys-
tem suppression, through superficial or soluble specific 
molecules actions.  
  CD46 is a membrane protien that protects cells against 
complement-mediated toxicity.  
  An immunohystochemistry assay on 73 ovarian cancer 
biopsies showed that CD46 expression is linked to a poor 
prognosis [64]. 
  RCAS1 (Receptor-binding cancer antigen expressed on 
SiSo cells) protein acts by inducing apoptosis in immune 
cells expressing the RCAS1 receptor, such as T cells and 
Natural Killer cells [65]. 
  By immuno-localization studies, a high RCAS1 expres-
sion was shown in breast, gallbladder and colorectal cancers 
[66, 67]. Patients with uterine cancer showed higher serum 
levels, compared to control; moreover, RCAS1 levels are 
correlated to therapy response [68]. 
ROLE OF THE PROTEOMICS IN THE IDENTIFICA-
TION OF BIOMARKERS OF OVARIAN CANCER 
  Over the past decade, the power of high-throughput tech-
nologies has stimulated their use in many bio-medical appli-
cations. In this field, proteomics has become an important 
methodology in the biomarker identification. Using this 
method the expression of hundreds of proteins can be studied 
simultaneously, by taking advantage of their different bio-
chemical properties.  
  This approach has been applied to ovarian cancer leading 
to the identification of several differentially expressed pro-
teins related to platinum resistance. Among these, five pro-
teins annexin A3, destrin, cofilin 1, GSTO1-1 and IDHc 
showed the more appreciable results, confirmed also by 
quantitative PCR and western blot [69].  
  Proteomics studies have also been applied to tumour 
classification by using diseased tissues and serum speci-
mens: Bengtsson et al. used DIGE technology to distinguish 
between benign and malignant tumour groups leading to the 
identification of an heterogeneous groups of proteins in-
volved in several cellular processes [70]. 
  By coupling laser capture microdissection and 2-DE, 
Brown Jones et al. revealed that the 52 KDa FK506 binding 
protein, RhoG-protein dissociation inhibitor and glyoxalase I 
were overexpressed in invasive ovarian cancer when com-
pared to low malignant potential ovarian tumours [71]. 
  The immune response to tumour associated antigens rep-
resents a possible serological tool for the diagnosis of cancer.  
  Autoantibodies direct against tumour associated antigens 
presented by MHC I molecules have been identified by liq-
uid chromatography - mass spectrometry/mass spectrometry 
(LC-MS/MS) using two human ovarian adenocarcinoma cell 
lines and serum sample from twenty patients, showing im-
portant implications in cancer detection and prognosis [72]. 
  Recently, emerging technologies are unravelling the 
plasma proteome.  
  Surface-enhanced laser desorption and ionization with 
time-of-flight spectrometry (SELDI-TOF) was employed for 
the rapid identification of serum proteins in ovarian cancer 
patients.  
  The strength of SELDI technology is based on the selec-
tive binding of proteins on a solid-phase protein chip surface 
where the sample is ionized by an energy laser impulse.  
  The protein profile of each specimen is then analysed by 
software to discovery changes in the protein pattern. Petri-
coin et al. [73] analyzed the serum of unaffected controls 
and patients with ovarian cancers and were able to discrimi-
nate with a sensibility of 100% and a specificity of 94% all 
ovarian cancers in the early stage [73].  
  Among the possible marker identified with SELDI there 
was the Haptoglobin, a glycoprotein secreted by liver cells 
and implicated in the metabolism of hemoglobulin.  
  High levels of Hp- subunit were found serum of patients 
with ovarian cancer.  
  The results of the ELISA test showed for Hp- a 64% 
sensitivity and 90% specificity alone and 91% sensitivity and 
95% specificity if combined with CA125.  
  Expression levels of 169 proteins were studied by Mor et 
al. by antibody microarray in serum of 28 healthy women, 
18 women newly diagnosed with EOC and 40 women with 
recurrent disease.  
  This analysis led to the identification of four proteins: 
leptin, prolactin, osteopontin, and insulin-like growth factor-
II. 
  Additional validation studies showed that the combina-
tion of the four proteins exhibited a sensitivity of 95%, a 
positive predictive value of 95%, a specificity of 95% and 
negative predictive value of 94% [74]. 
CONCLUSION 
  Because of a lack of specific symptoms in the early phase 
and the limitations of existing markers for diagnostic meth-340    Current Genomics, 2007, Vol. 8, No. 5  Tinelli et al. 
ods, the ovarian cancer still represent, despite its low inci-
dence, one of the leading cause of death worldwide.  
  Proteomics and genomics provide a central opportunity 
for the rapid identification and development of novel detect-
able biomarkers; however, the current technologies show 
some limitations.  
  Nevertheless, the study of low-abundant proteins and the 
need to analyze a large body of sample to extrapolate signifi-
cant results, make the proteomics approach labour-intensive 
and the potential of a gene therapy for ovarian cancer, that 
involves blocking expression of specific ovarian oncogenes, 
seems to be far to be applied. 
  Currently, many genomic tests used to diagnose ovarian 
cancer or guide its therapy do not decrease women's risk of 
dying from this disease or do not improve their quality of life 
(QoL). 
  Therefore, for their rapid investigations of biological 
specimens mass spectrometry and protein arrays are evolv-
ing as alternative methodologies to the “classic proteomics 
approach” facilitating their use at many points of the disease 
management and the expanding our knowledge on biomark-
ers is likely to lead to more individualization of therapy and 
improvements in ovarian cancer prognosis. 
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